Species-dependent functionality of the human cytolytic fusion proteins Granzyme B-H22(scFv) and H22(scFv)-angiogenin in macrophages

Antibodies

Volumn 2, Issue 1, 2013, Pages 9-18

  Schiffer, Sonja ^a,b   Hristodorov, Dmitrij ^a   Mladenov, Radoslav ^a   Aslanian, Eric ^a   Huhn, Michael ^a   Fischer, Rainer ^a,c   Barth, Stefan ^a,b   Thepen, Theo ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

CD64; Immunotoxin; Inflammation; Mouse model

Indexed keywords

ANGIOGENIN; CD64 ANTIGEN; GRANZYME B; GRANZYME B H22(SCFV); H22(SCFV) ANGIOGENIN; RIBONUCLEASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL ACTIVITY; CELL ISOLATION; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN SYNTHESIS;

EID: 84887141347     PISSN: 20734468     EISSN: None     Source Type: Journal    
DOI: 10.3390/antib2010009     Document Type: Article

References (36)

1. Kreitman, R. J. Recombinant toxins for the treatment of cancer. Curr. Opin. Mol. Ther. 2003, 5, 44-51.
2. Allen, T. M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2002, 2, 750-763.
3. Cawley, D. B.; Herschman, H. R.; Gilliland, D. G.; Collier, R. J. Epidermal growth factor-toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxic. Cell 1980, 22, 563-570.
4. Williams, D. P.; Parker, K.; Bacha, P.; Bishai, W.; Borowski, M.; Genbauffe, F.; Strom, T. B.; Murphy, J. R. Diphtheria toxin receptor binding domain substitution with interleukin-2: Genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng. 1987, 1, 493-498.
5. Zhou, X. X.; Ji, F.; Zhao, J. L.; Cheng, L. F.; Xu, C. F. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells. J. Gastroenterol. Hepatol. 2010, 25, 1266-1275.
6. Hu, C. C.; Ji, H. M.; Chen, S. L.; Zhang, H. W.; Wang, B. Q.; Zhou, L. Y.; Zhang, Z. P.; Sun, X. L.; Chen, Z. Z.; Cai, Y. Q.; et al. Investigation of a plasmid containing a novel immunotoxin VEGF165-PE38 gene for antiangiogenic therapy in a malignant glioma model. Int. J. Cancer 2010, 127, 2222-2229.
7. Hristodorov, D.; Mladenov, R.; Huhn, M.; Barth, S.; Thepen, T. Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases. Toxins 2012, 4, 676-694.
8. Barta, S. K.; Zou, Y.; Schindler, J.; Shenoy, N.; Bhagat, T. D.; Steidl, U.; Verma, A. Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia. Leukemia Lymphoma 2012, 53, 1999-2003.
9. Schnell, R.; Vitetta, E.; Schindler, J.; Borchmann, P.; Barth, S.; Ghetie, V.; Hell, K.; Drillich, S.; Diehl, V.; Engert, A. Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia 2000, 14, 129-135.
10. Pai, L. H.; Pastan, I. Clinical trials with Pseudomonas exotoxin immunotoxins. Curr. Top. Microbiol. Immunol. 1998, 234, 83-96.
11. Frankel, A. E.; Powell, B. L.; Hall, P. D.; Case, L. D.; Kreitman, R. J. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin. Cancer Res. 2002, 8, 1004-1013.
12. Furman, R. R.; Grossbard, M. L.; Johnson, J. L.; Pecora, A. L.; Cassileth, P. A.; Jung, S. H.; Peterson, B. A.; Nadler, L. M.; Freedman, A.; Bayer, R. L.; et al. A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leukemia Lymphoma 2011, 52, 587-596.
13. Kreitman, R. J.; Tallman, M. S.; Robak, T.; Coutre, S.; Wilson, W. H.; Stetler-Stevenson, M.; Fitzgerald, D. J.; Lechleider, R.; Pastan, I. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J. Clin. Oncol. 2012, 30, 1822-1828.
14. Mathew, M.; Verma, R. S. Humanized immunotoxins: A new generation of immunotoxins for targeted cancer therapy. Cancer Sci. 2009, 100, 1359-1365.
15. Trapani, J. A. Granzymes: A family of lymphocyte granule serine proteases. Genome Biol. 2001, 2, REVIEWS3014.
16. Metkar, S. S.; Wang, B.; Ebbs, M. L.; Kim, J. H.; Lee, Y. J.; Raja, S. M.; Froelich, C. J. Granzyme B activates procaspase-3 which signals a mitochondrial amplification loop for maximal apoptosis. J. Cell Biol. 2003, 160, 875-885.
17. Trapani, J. A.; Jans, P.; Smyth, M. J.; Froelich, C. J.; Williams, E. A.; Sutton, V. R.; Jans, D. A. Perforin-dependent nuclear entry of granzyme B precedes apoptosis, and is not a consequence of nuclear membrane dysfunction. Cell Death Differ. 1998, 5, 488-496.
18. Barry, M.; Heibein, J. A.; Pinkoski, M. J.; Lee, S. F.; Moyer, R. W.; Green, D. R.; Bleackley, R. C. Granzyme B short-circuits the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte killing by directly cleaving Bid. Mol. Cell. Biol. 2000, 20, 3781-3794.
19. Andrade, F.; Casciola-Rosen, L. A.; Rosen, A. Granzyme B-induced cell death. Acta Haematol. 2004, 111, 28-41.
20. Schirrmann, T.; Krauss, J.; Arndt, M. A.; Rybak, S. M.; Dubel, S. Targeted therapeutic RNases (ImmunoRNases). Expert Opin. Biol. Ther. 2009, 9, 79-95.
21. Saxena, S. K.; Rybak, S. M.; Davey, R. T., Jr.; Youle, R. J.; Ackerman, E. J. Angiogenin is a cytotoxic, tRNA-specific ribonuclease in the RNase A superfamily. J. Biol. Chem. 1992, 267, 21982-21986.
22. Stahnke, B.; Thepen, T.; Stocker, M.; Rosinke, R.; Jost, E.; Fischer, R.; Tur, M. K.; Barth, S. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol. Cancer Ther. 2008, 7, 2924-2932.
23. Huhn, M.; Sasse, S.; Tur, M. K.; Matthey, B.; Schinkothe, T.; Rybak, S. M.; Barth, S.; Engert, A. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res. 2001, 61, 8737-8742.
24. Liu, Y.; Cheung, L. H.; Hittelman, W. N.; Rosenblum, M. G. Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents. Mol. Cancer Ther. 2003, 2, 1341-1350.
25. Zhang, L.; Zhao, J.; Wang, T.; Yu, C. J.; Jia, L. T.; Duan, Y. Y.; Yao, L. B.; Chen, S. Y.; Yang, A. G. HER2-targeting recombinant protein with truncated pseudomonas exotoxin A translocation domain efficiently kills breast cancer cells. Cancer Biol. Ther. 2008, 7, 1226-1231.
26. Hetzel, C.; Bachran, C.; Fischer, R.; Fuchs, H.; Barth, S.; Stocker, M. Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells. J. Immunother. 2008, 31, 370-376.
27. Stahnke, B.; Thepen, T.; Stocker, M.; Rosinke, R.; Jost, E.; Fischer, R.; Tur, M. K.; Barth, S. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol. Cancer Ther. 2008, 7, 2924-2932.
28. Tur, M. K.; Huhn, M.; Jost, E.; Thepen, T.; Brummendorf, T. H.; Barth, S. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model. Int. J. Cancer 2011, 129, 1277-1282.
29. van Roon, J. A.; van Vuuren, A. J.; Wijngaarden, S.; Jacobs, K. M.; Bijlsma, J. W.; Lafeber, F. P.; Thepen, T.; van de Winkel, J. G. Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcgamma receptor I-directed immunotoxin. Arthrit. Rheum. 2003, 48, 1229-1238.
30. van Vuuren, A. J.; van Roon, J. A.; Walraven, V.; Stuij, I.; Harmsen, M. C.; McLaughlin, P. M.; van de Winkel, J. G.; Thepen, T. CD64-directed immunotoxin inhibits arthritis in a novel CD64 transgenic rat model. J. Immunol. 2006, 176, 5833-5838.
31. Ribbert, T.; Thepen, T.; Tur, M. K.; Fischer, R.; Huhn, M.; Barth, S. Recombinant, ETA'-based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice. Br. J. Dermatol. 2010, 163, 279-286.
32. Tur, M. K.; Huhn, M.; Thepen, T.; Stocker, M.; Krohn, R.; Vogel, S.; Jost, E.; Osieka, R.; van de Winkel, J. G.; Fischer, R.; et al. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. Cancer Res. 2003, 63, 8414-8419.
33. de Poot, S. A. H.; Westgeest, M.; Hostetter, D. R.; Van Damme, P.; Plasman, K.; Demeyer, K.; Broekhuizen, R.; Gevaert, K.; Craik, C. S.; Bovenschen, N. Human and mouse granzyme M display divergent and species-specific substrate specificities. Biochem. J. 2011, 437, 431-442.
34. Kaiserman, D.; Bird, C. H.; Sun, J. R.; Matthews, A.; Ung, K.; Whisstock, J. C.; Thompson, P. E.; Trapani, J. A.; Bird, P. I. The major human and mouse granzymes are structurally and functionally divergent. J. Cell Biol. 2006, 175, 619-630.
35. Cullen, S. P.; Adrain, C.; Luthi, A. U.; Duriez, P. J.; Martin, S. J. Human and murine granzyme B exhibit divergent substrate preferences. J. Cell Biol. 2007, 176, 435-44.
36. Bots, M.; Van Bostelen, L.; Rademaker, M. T.; Offringa, R.; Medema, J. P. Serpins prevent granzyme-induced death in a species-specific manner. Immunol. Cell Biol. 2006, 84, 79-86.